chf

Nexstim Plc successfully completes its Initial Public Offering - subscriptions reach € 15.3 million with final offer price of € 6.35 per share

on 04/11/2014 15:37

iSTAR Medical Announces First Patient Implanted with STARflo Glaucoma Drainage Device in European Clinical Trial

on 30/10/2014 10:40
1st patient in EU trial
Read more

Nexstim progresses its navigated brain stimulation technology in stroke and demonstrates improved outcomes in brain tumor surgery

on 28/08/2014 10:21
Study on track and sites selected and initiated in multicenter clinical trial on the therapeutic effects of NBT® for stroke rehabilitation.
Read more

iSTAR Medical appoints Michel Vanbrabant Chief Executive Officer

on 16/07/2014 11:40
iSTAR Medical SA announced today that Michel Vanbrabant has been appointed Chief Executive Officer and member of the Board of Directors.
Read more

Mainstay Medical Announces Pre-IDE Submission for ReActiv8® to FDA

on 07/07/2014 11:26
Mainstay Medical continues progress towards the commercialisation of ReActiv8.
Read more